FM
GSK icon

Foster & Motley’s GSK GSK Stock Holding History

Foster & Motley’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Sell
42,484
-625
-1% -$33.1K 0.1% 162
2026
Q1 		$2.38M Buy
43,109
+7,272
+20% +$394K 0.12% 154
2025
Q4 		$1.76M Buy
35,837
+5,251
+17% +$245K 0.09% 174
2025
Q3 		$1.32M Buy
30,586
+3,256
+12% +$127K 0.07% 203
2025
Q2 		$1.05M Buy
27,330
+5,700
+26% +$218K 0.06% 219
2025
Q1 		$838K Sell
21,630
-1,208
-5% -$44.2K 0.05% 231
2024
Q4 		$772K Buy
22,838
+2,508
+12% +$90.3K 0.05% 239
2024
Q3 		$831K Buy
20,330
+6,708
+49% +$274K 0.05% 228
2024
Q2 		$524K Buy
+13,622
New +$573K 0.04% 260

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Foster & Motley's GSK Position: Q2 2026 in Review

Foster & Motley reduced its GSK (GSK) stake by 1.4% in Q2 2026, selling an estimated $33.1K and leaving 42,484 shares worth $2.23M. The position accounts for 0.1% of the portfolio, ranked #162.

Foster & Motley first reported a position in GSK in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.38M in Q1 2026. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Foster & Motley held 42,484 shares of GSK worth $2.23M as of Q2 2026.
  • Foster & Motley sold 625 GSK shares in Q2 2026, an estimated $33.1K.
  • GSK made up 0.1% of Foster & Motley's portfolio in Q2 2026, its #162 holding.
  • Foster & Motley first reported a position in GSK in Q2 2024 and has held it in 9 quarters since.
  • Foster & Motley's GSK position peaked at $2.38M in Q1 2026.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Foster & Motley's 13F filing for Q2 2026, filed 7 Aug 2026.